A carregar...
Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma is Ready for Primetime
The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose melphalan with autologous stem cell transplant (HDM-ASCT). In 2015 alone, the US Food and Drug Administration (FDA) approved 4 novel drugs for MM. Novel drug...
Na minha lista:
| Publicado no: | Clin Adv Hematol Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7451402/ https://ncbi.nlm.nih.gov/pubmed/31730582 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|